Abstract

This current issues paper addresses the significant metabolic burden associated with the use of second-generation antipsychotics (SGAs). These medications are effective in managing various psychiatric disorders. However, patients taking SGAs often experience common side effects, such as weight gain, insulin resistance, dyslipidemia, and an increased risk of metabolic syndrome (Speyer et al., 2021; Welge et al., 2023). These common adverse/side effects can severely impact the physical health and overall quality of life of patients, including mental health and self-esteem (Blasco et al., 2020). Over time, these effects may lead to long-term health complications, including cardiovascular disease and type 2 diabetes. Hence, while supporting psychiatric symptom management, these medications can simultaneously create a major challenge for both patients and healthcare providers (Welge et al., 2023). The opportunity for improvement lies in recognizing and incorporating effective strategies to manage these side effects (Pearl et al., 2023; Wajid et al., 2023). Practitioners must ensure that psychiatric patients do not face additional health risks because of their psychiatric treatment. This discussion paper seeks to provide sensible solutions to lessen or alleviate the metabolic risks associated with SGAs through integration of adjunct therapies, such as Topamax (topiramate), metformin, and GLP-1 receptor agonists (Vanderah, 2024, Pearl et al., 2023; Wajid et al., 2023). The integration of this intervention could significantly improve patient outcomes by addressing the dual challenge of maintaining metabolic health while managing psychiatric symptoms, ultimately improving patient outcomes and quality of life.

Keywords: Second-Generation Antipsychotics, Metabolic Syndrome, GLP-1 Receptor Agonists, Topiramate, Psychiatric Treatment, Cardiometabolic Risk

How to Cite:

Pressley, T. & Russell, N., (2026) “Mind and Metabolism in Harmony: Addressing the Metabolic Side Effects of Second-Generation Antipsychotics with Topamax, Metformin, and GLP-1 Agonists”, Health Behavior Research 9(1).